Unity Biotechnology, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2025-09-26: Form 8-K; Period of report 2025-09-24; Description 1.02 Termination of a Material Definitive Agreement; 3.03 Material Modification to Rights of Security Holders; Details 1.02.
- 2025-09-19: Form 8-K; Period of report 2025-09-18; Description 5.07 Submission of Matters to a Vote of Security Holders; Details 5.07.
- 2025-07-24: Form 8-K/A; Period of report 2025-07-21; Description 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Details 1.01.
- 2025-07-22: Form 8-K; Period of report 2025-07-21; Description 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2025-09-26 | 8-K | 2025-09-24 | 1.02 Termination of a Material Definitive Agreement; 3.03 Material Modification to Rights of Security Holders | 1.02 On September 24, 2025, Unity Biotechnology, Inc. (the “Company”) entered into a Lease Termination Agreement and Amendment (the “Lease Termination Agreement”) with Bayside Area Development, LLC, a Delaware limited liability company (the “Landlord”), pursuant to which the Company and Landlord agreed to terminate that certain Lease, dated February 29, 2019, as amended (the “Original Lease”), related to the Company’s office and laboratory space located at 285 E. Grand Avenue, South San Francisco, CA 94080. 3.03 As previously reported, on June 27, 2025, the Board approved the Dissolution under the DGCL pursuant to the Plan of Dissolution. | d190494d8k.htm |
| 2025-09-19 | 8-K | 2025-09-18 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On September 18, 2025, Unity Biotechnology, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”). | d804178d8k.htm |
| 2025-07-24 | 8-K/A | 2025-07-21 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 1.01 Entry into a Material Definitive Agreement. 3.02 The disclosure included in Item 1.01 and Item 5.03 of this report is incorporated under this Item by reference. 3.03 The disclosure included in Item 5.03 of this report is incorporated under this Item by reference. 5.03 On July 21, 2025, the Company filed the Certificate of Designation of Series A Preferred Stock with the Secretary of State of the State of Delaware, which sets forth the rights, preferences and privileges of the Series A Preferred Share. | d84300d8ka.htm |
| 2025-07-22 | 8-K | 2025-07-21 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 1.01 Entry into a Material Definitive Agreement. 3.02 The disclosure included in Item 1.01 and Item 5.03 of this report is incorporated under this Item by reference. 3.03 The disclosure included in Item 5.03 of this report is incorporated under this Item by reference. 5.03 On July 21, 2025, the Company filed the Certificate of Designation of Series A Preferred Stock with the Secretary of State of the State of Delaware, which sets forth the rights, preferences and privileges of the Series A Preferred Share. | d921163d8k.htm |
| 2025-06-30 | 8-K | 2025-06-27 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 3.01 On June 27, 2025, UNITY Biotechnology, Inc. (“UNITY” or the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, as a result of (i) the events disclosed in the Company’s Current Report on Form 8-K filed on May 5, 2025, including the implementation of a substantial reduction in force and the board of director’s approval of an operating plan to evaluate strategic alternatives while reducing operational cash burn, including the closing out of the Company’s ASPIRE study, and (ii) the Staff’s assessment of the Company’s financial projections, limited operations, lack of revenue, and minimal continued investment in the development of a revenue-producing asset, it is the Staff’s belief that the Company no longer has an operating business and is a “public shell” and that continued listing of its securities on Nasdaq is no longer warranted. 5.02 On June 27, 2025, in connection with the planned Dissolution (as defined below), each of Nathaniel E. David, Ph.D., Anirvan Ghosh, Ph.D., Yehia Hashad, M.D., Keith R. Leonard Jr., Gilmore O’Neill, M.B., Margo Roberts, Ph.D., Michael P. Samar, and Camille D. Samuels notified the Company of their resignation from the Board of Directors (the “Board”) of the Company and all committees thereof, effective as of 5:00 p.m. 8.01 On June 27, 2025, the Board: (i) determined that it is in the best interests of UNITY and its stockholders that the Company be dissolved in accordance with the General Corporation Law of the State of Delaware pursuant to a Plan of Dissolution (the “Dissolution”); (ii) approved the Dissolution; and (iii) approved seeking stockholder approval to proceed with the Dissolution pursuant to Delaware law (the “Dissolution Proposal”) at a special meeting of stockholders (the “Special Meeting of Stockholders”) to be held as soon as reasonably practicable. | ubx-20250627.htm |
| 2025-06-20 | 8-K | 2025-06-18 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On June 18, 2025, Unity Biotechnology, Inc. (the “Company”) received a notification from The Nasdaq Stock Market (“Nasdaq”) that for the last 30 consecutive business days, the closing bid price of the Company’s common stock was below $1.00 per share, which is the minimum required closing bid price for continued listing on the Nasdaq Global Select Market pursuant to Listing Rule 5450(a)(1). | ubx-20250618.htm |
| 2025-05-05 | 8-K | 2025-05-02 | 2.05 Costs Associated with Exit or Disposal Activities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 2.05 On May 2, 2025, the Board of Directors (the “Board”) of UNITY Biotechnology, Inc., a Delaware corporation (“UNITY” or the “Company”) approved a plan (the “Operating Plan”) to reduce operating costs and preserve capital following the disclosure of full 36-week data from the Company’s ASPIRE study, discussed further under Item 8.01 of this Current Report on Form 8-K. As part of the Operating Plan, the Company is implementing a reduction in force affecting all of its employees and is entering into consulting agreements to retain certain personnel to support the Company in evaluating strategic alternatives and executing on the Operating Plan. 5.02 In connection with the reduction in force described under Item 2.05 above and pursuant to the Operating Plan, each of Anirvan Ghosh, Lynne Sullivan, and Alexander Nguyen, the Company’s Chief Executive Officer, Chief Financial Officer and Head of Corporate Development, and Chief Legal Officer and Head of Operations, respectively, will terminate employment with the Company, effective May 15, 2025, but continue to support the Company on a part-time advisory basis pursuant to the terms of a consulting agreement to be entered into with the Company. 8.01 On May 5, 2025, the Company announced the full 36-week topline results from its Phase 2b ASPIRE clinical trial evaluating UBX1325 (foselutoclax) for the treatment of diabetic macular edema. | ubx-20250502.htm |
| 2025-04-22 | 8-K | 2025-04-22 | 2.02 Results of Operations and Financial Condition | 2.02 On April 22, 2025, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2025. | ubx-20250422.htm |
| 2025-04-04 | 8-K | 2025-04-03 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 3, 2025, Paul L. Berns informed the Board of Directors (the “Board”) of UNITY Biotechnology, Inc. (“Unity” or the “Company”) of his resignation as a member of the Board of the Company, and all of the committees of the Board on which he serves, in each case, effective at the close of business on April 4, 2025. | ubx-20250403.htm |
| 2025-03-24 | 8-K | 2025-03-24 | 8.01 Other Events | 8.01 On March 24, 2025, UNITY Biotechnology, Inc. (“Unity” or the “Company”) announced topline results from its ASPIRE Phase 2b study in patients with diabetic macular edema (DME). | ubx-20250324.htm |
| 2025-03-17 | 8-K | 2025-03-14 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On March 14, 2025, UNITY Biotechnology, Inc. (“Unity” or the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that its stockholders’ equity as reported in its Annual Report on Form 10-K had fallen below the minimum stockholders’ equity requirement of at least $10,000,000 for continued listing on The Nasdaq Global Select Market set forth in Nasdaq Listing Rule 5450(b)(1)(A). | ubx-20250314.htm |
| 2025-03-10 | 8-K | 2025-03-08 | 5.01 Changes in Control of Registrant; 8.01 Other Events | 8.01 On March 10, 2025, UNITY issued a press release announcing the foregoing matters. | ubx-20250308.htm |
| 2025-03-07 | 8-K | 2025-03-07 | 2.02 Results of Operations and Financial Condition | 2.02 On March 7, 2025, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2024. | ubx-20250307.htm |
| 2025-01-06 | 8-K | 2025-01-01 | 8.01 Other Events | 8.01 On January 1, 2025, Unity Biotechnology, Inc. (“Unity” or the “Company”) appointed Federico Grossi, M.D., Ph.D., as the Company’s Chief Medical Officer, effective immediately. | ubx-20250101.htm |
| 2024-11-04 | 8-K | 2024-11-04 | 2.02 Results of Operations and Financial Condition | 2.02 On November 4, 2024, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2024. | ubx-20241104.htm |
| 2024-08-06 | 8-K | 2024-08-06 | 2.02 Results of Operations and Financial Condition | 2.02 On August 6, 2024, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the second quarter ended June 30, 2024. | ubx-20240806.htm |
| 2024-06-21 | 8-K | 2024-06-21 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 21, 2024, Unity Biotechnology, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). | ubx-20240621.htm |
| 2024-05-14 | 8-K | 2024-05-14 | 2.02 Results of Operations and Financial Condition | 2.02 On May 14, 2024, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2024. | ubx-20240514.htm |
| 2024-04-15 | 8-K | 2024-04-15 | 2.02 Results of Operations and Financial Condition | 2.02 On April 15, 2024, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2023. | ubx-20240415.htm |
| 2024-03-20 | 8-K | 2024-03-19 | 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review | 4.02 On March 19, 2024, the Audit Committee (the “Audit Committee”) of the Board of Directors of UNITY Biotechnology, Inc. (the “Company”), after consultation with management, determined that the Company incorrectly classified its warrants (the “Warrants”) that were issued in August 2022 as equity which should have been recorded as liabilities and measured at fair value at each balance sheet date. | ubx-20240319.htm |
| 2023-11-13 | 8-K | 2023-11-13 | 2.02 Results of Operations and Financial Condition | 2.02 On November 13, 2023, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2023. | ubx-20231113.htm |
| 2023-11-13 | 8-K | 2023-11-09 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 3.02 The New Warrants and the Placement Agent Warrants will be issued pursuant to the exemption from the registration requirements of the Securities Act available under Section 4(a)(2). 7.01 On November 10, 2023, the Company issued a press release announcing the transactions contemplated pursuant to the Inducement Letter. | ubx-20231109.htm |
| 2023-09-27 | 8-K | 2023-09-27 | 8.01 Other Events | 8.01 On September 27, 2023, Unity Biotechnology, Inc. (“UNITY” or the “Company”) announced data from Part B of its Phase 2 ENVISION study of UBX1325 in patients with wet age-related macular degeneration (AMD). | ubx-20230927.htm |
| 2023-09-06 | 8-K | 2023-09-06 | 1.02 Termination of a Material Definitive Agreement | 1.02 As previously disclosed, on August 3, 2020, UNITY Biotechnology, Inc. (the “Company”) entered into a Loan and Security Agreement (as amended, restated, supplemented or otherwise modified, the “Hercules Loan Agreement”) with Hercules Capital, Inc. (“Hercules”), as administrative agent and collateral agent for the lenders, and certain banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), for an aggregate principal amount of up to $80.0 million secured term loan facility (the “Hercules Facility”) subject to certain terms and conditions. | ubx-20230906.htm |
| 2023-08-08 | 8-K | 2023-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2023, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the second quarter ended June 30, 2023. | ubx-20230809.htm |
| 2023-06-23 | 8-K | 2023-06-23 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 23, 2023, Unity Biotechnology, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). | ubx-20230623.htm |
| 2023-05-09 | 8-K | 2023-05-09 | 2.02 Results of Operations and Financial Condition | 2.02 On May 9, 2023, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2023. | ubx-20230509.htm |
| 2023-04-28 | 8-K/A | 2023-04-10 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 This filing amends Item 5.02 of the Current Report on Form 8-K filed by Unity Biotechnology, Inc. (the “Company”) with the Securities and Exchange Commission on April 11, 2023. | ubx-20230410.htm |
| 2023-04-24 | 8-K | 2023-04-24 | 8.01 Other Events | 8.01 On April 24, 2023, Unity Biotechnology, Inc. (“UNITY” or the “Company”) announced positive 48-week data from its Phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema (DME). | ubx-20230424.htm |
| 2023-04-11 | 8-K | 2023-04-10 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 10, 2023, Unity Biotechnology, Inc. (the “Company”) and Jamie Dananberg agreed that Dr. Dananberg would be leaving his employment with the Company on April 30, 2023. | ubx-20230410.htm |
| 2023-03-27 | 8-K | 2023-03-27 | 8.01 Other Events | 8.01 On March 27, 2023, Unity Biotechnology, Inc. (“UNITY” or the “Company”) announced data from its Phase 2 ENVISION study of UBX1325 in patients with wet age-related macular degeneration (AMD). | ubx-20230327.htm |
| 2023-03-17 | 8-K | 2023-03-17 | 8.01 Other Events | 8.01 On March 17, 2023, Unity Biotechnology, Inc. (the “Company”) entered into Amendment No. 2 (the “Amendment No. 2”) to the Sales Agreement, dated March 15, 2022, as amended by Amendment No. 1 thereto dated August 17, 2022 (together with Amendment No. 2, the “Sales Agreement”), with Cowen and Company, LLC (“Cowen”), in connection with the continuation of the Company’s at-the-market equity offering program (the “Program”). | d493524d8k.htm |
| 2023-03-15 | 8-K | 2023-03-15 | 2.02 Results of Operations and Financial Condition | 2.02 On March 15, 2023, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2022. | ubx-20230315.htm |
| 2023-03-13 | 8-K | 2023-03-10 | 7.01 Regulation FD Disclosure | 7.01 Unity Biotechnology, Inc. (“Unity”) is aware of media reports indicating that Silicon Valley Bank (“SVB”) has been closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation as receiver. | d482844d8k.htm |
| 2022-11-08 | 8-K | 2022-11-08 | 2.02 Results of Operations and Financial Condition | 2.02 On November 8, 2022, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2022. | ubx-20221108.htm |
| 2022-11-01 | 8-K | 2022-11-01 | 8.01 Other Events | 8.01 On November 1, 2022, Unity Biotechnology, Inc. (“UNITY” or the “Company”) announced positive 24-week data from its Phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema (DME). | ubx-20221101.htm |
| 2022-10-19 | 8-K | 2022-10-18 | 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events | 3.03 To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference. 5.03 On October 19, 2022, Unity Biotechnology, Inc. (the “Company”) effected a 1-for-10 reverse stock split of its common stock (the “Reverse Stock Split”). 5.07 As reported in Item 5.03 above, on October 18, 2022, the Company held the Special Meeting. 8.01 On October 19, 2022, the Company issued a press release announcing the Reverse Stock Split. | d400459d8k.htm |
| 2022-08-22 | 8-K | 2022-08-17 | 8.01 Other Events | 8.01 On August 17, 2022, Unity Biotechnology, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with SVB Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell 64,285,714 shares (the “Shares”) of its common stock, par value $0.0001 per share (“Common Stock”), and accompanying warrants to purchase up to 64,285,714 shares of Common Stock (the “Warrants”) at a combined public offering price of $0.70 per Share and accompanying Warrant to the Underwriters (the “Offering”). | d583643d8k.htm |
| 2022-08-19 | 8-K | 2022-08-17 | 8.01 Other Events | 8.01 On August 17, 2022, Unity Biotechnology, Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to the Sales Agreement dated March 15, 2022 (as amended, the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”), which Amendment decreases the amount of the Company’s common stock, par value $0.0001 per share (the “Shares”), that can be sold by the Company through Cowen, as the Company’s agent and/or principal under the Sales Agreement, from an aggregate offering price of up to $50,000,000 to an aggregate offering price of up to $25,000,000. | d379448d8k.htm |
| 2022-08-12 | 8-K | 2022-08-12 | 2.02 Results of Operations and Financial Condition | 2.02 On August 12, 2022, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the second quarter ended June 30, 2022 and provided business updates. | ubx-8k_20220812.htm |
| 2022-08-12 | 8-K | 2022-08-12 | 8.01 Other Events | 8.01 On August 12, 2022, Unity Biotechnology, Inc. (“UNITY” or the “Company”) announced positive data from its Phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema (DME). | d379677d8k.htm |
| 2022-07-05 | 8-K | 2022-07-05 | 8.01 Other Events | 8.01 On June 24, 2022, Unity Biotechnology, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders (the “Annual Meeting”) during which, among other proposals, the Company’s stockholders voted on a series of alternate amendments to the Company’s amended and restated certificate of incorporation, to effect, at the discretion of the Company’s Board of Directors, a reverse stock split of the Company’s common stock, whereby each outstanding 5, 6, 7, 8, 9, or 10 shares would be combined, converted, and changed into one share of common stock (referred to in the Company’s definitive proxy statement in connection with the Annual Meeting, as Proposal No. 3). | ubx-8k_20220705.htm |
| 2022-06-27 | 8-K | 2022-06-24 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 24, 2022, Unity Biotechnology, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). | ubx-8k_20220624.htm |
| 2022-06-07 | 8-K | 2022-06-03 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On June 3, 2022, Unity Biotechnology, Inc. (the “Company”) received a notification from The Nasdaq Stock Market (“Nasdaq”) that for the last 30 consecutive business days, the closing bid price of the Company’s common stock was below $1.00 per share, which is the minimum required closing bid price for continued listing on the Nasdaq Global Select Market pursuant to Listing Rule 5450(a)(1). | ubx-8k_20220603.htm |
| 2022-05-26 | 8-K | 2022-05-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On May 25, 2022, the Board of Directors (the “Board”) of UNITY Biotechnology, Inc. (“Unity” or the “Company”) appointed Michael Samar to the Board and as Chair of the Company’s Audit Committee and a member of the Compensation Committee effective immediately. 8.01 On May 26, 2022, UNITY issued a press release announcing the foregoing matters. | ubx-8k_20220525.htm |
| 2022-05-10 | 8-K | 2022-05-10 | 2.02 Results of Operations and Financial Condition | 2.02 On May 10, 2022, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2022. | ubx-8k_20220510.htm |
| 2022-04-01 | 8-K | 2022-03-31 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | ubx-8k_20220331.htm | |
| 2022-03-15 | 8-K | 2022-03-15 | 2.02 Results of Operations and Financial Condition | 2.02 On March 15, 2022, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2021. | ubx-8k_20220315.htm |
| 2022-02-03 | 8-K | 2022-02-02 | 2.05 Costs Associated with Exit or Disposal Activities | 2.05 On February 2, 2022, the Board of Directors (the “Board”) of UNITY Biotechnology, Inc., a Delaware corporation (“UNITY” or the “Company”), implemented a corporate restructuring (the “Restructuring”) to align its resources to focus on its UBX1325 program while further extending operating capital. | ubx-8k_20220202.htm |
| 2021-12-20 | 8-K | 2021-12-17 | 8.01 Other Events | 8.01 On December 17, 2021, Unity Biotechnology, Inc. (“Unity” or the “Company”) entered into an exclusive license agreement with Jocasta Neuroscience, Inc. to continue development of the α-Klotho program. | ubx-8k_20211217.htm |
| 2021-12-15 | 8-K | 2021-12-15 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | ubx-8k_20211215.htm |
| 2021-11-10 | 8-K | 2021-11-10 | 2.02 Results of Operations and Financial Condition | 2.02 On November 10, 2021, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2021. | ubx-8k_20211110.htm |
| 2021-09-29 | 8-K | 2021-09-29 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d222119d8k.htm |
| 2021-08-10 | 8-K | 2021-08-10 | 2.02 Results of Operations and Financial Condition | 2.02 On August 10, 2021, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the second quarter ended June 30, 2021. | ubx-8k_20210810.htm |
| 2021-07-07 | 8-K/A | 2021-07-06 | 9.01 Financial Statements and Exhibits | 9.01 Reference is made to the Exhibit Index attached hereto. | ubx-8ka_20210706.htm |
| 2021-07-06 | 8-K | 2021-07-06 | 8.01 Other Events | 8.01 On July 6, 2021, UNITY Biotechnology, Inc. (“UNITY” or the “Company”) announced positive data from its Phase 1 safety study of UBX1325 in patients with advanced disease from diabetic macular edema (DME) or wet or neovascular age-related macular degeneration (AMD) for whom anti-VEGF therapy was no longer considered beneficial. | ubx-8k_20210706.htm |
| 2021-06-24 | 8-K | 2021-06-24 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 24, 2021, Unity Biotechnology, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). | ubx-8k_20210624.htm |
| 2021-05-11 | 8-K | 2021-05-11 | 2.02 Results of Operations and Financial Condition | 2.02 On May 11, 2021, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2021. | ubx-8k_20210511.htm |
| 2021-03-23 | 8-K | 2021-03-23 | 2.02 Results of Operations and Financial Condition | 2.02 On March 23, 2021, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2020. | ubx-8k_20210323.htm |
| 2020-12-14 | 8-K | 2020-12-09 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On December 10, 2020, the Board of Directors (the “Board”) of UNITY Biotechnology, Inc. (“Unity” or the “Company”) appointed Gilmore O’Neill to the Board and as Chair of the Company’s Science Committee effective immediately. 8.01 On December 14, 2020, UNITY issued a press release announcing the foregoing matters. | d62670d8k.htm |
| 2020-11-04 | 8-K | 2020-11-04 | 2.02 Results of Operations and Financial Condition | 2.02 On November 4, 2020, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2020. | ubx-8k_20201104.htm |
| 2020-09-24 | 8-K | 2020-09-21 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 21, 2020, Alexander Azoy, the Vice President of Finance, Chief Accounting Officer of UNITY Biotechnology, Inc., a Delaware corporation (the “Company”), notified the Company of his decision to pursue other opportunities and resign from his position at the Company effective October 2, 2020. | d77083d8k.htm |
| 2020-09-16 | 8-K | 2020-09-10 | 2.05 Costs Associated with Exit or Disposal Activities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.05 On September 10, 2020, the Board of Directors (the “Board”) of UNITY Biotechnology, Inc., a Delaware corporation (“UNITY” or the “Company”), implemented a corporate restructuring (the “Restructuring”) to align its resources on cellular senescence programs in ophthalmology and neurology while further extending operating capital. 5.02 On September 10, 2020, the Board appointed Alexander Azoy, the Company’s Vice President of Finance, Chief Accounting Officer, as the principal accounting officer, effective immediately. | d899293d8k.htm |
| 2020-08-31 | 8-K | 2020-08-28 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 28, 2020, the Board of Directors (the “Board”) of UNITY Biotechnology, Inc., a Delaware corporation (“UNITY” or the “Company”), appointed Lynne Sullivan as the Company’s Chief Financial Officer effective as of September 1, 2020. | d91302d8k.htm |
| 2020-08-17 | 8-K | 2020-08-17 | 8.01 Other Events | 8.01 On August 17, 2020, UNITY Biotechnology, Inc. (“UNITY” or the “Company”) announced the 12-week results from its Phase 2 study of UBX0101 in patients with moderate-to-severe painful osteoarthritis (OA) of the knee. | d28349d8k.htm |
| 2020-08-04 | 8-K | 2020-08-03 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 7.01 Regulation FD Disclosure | 1.01 Effective as of August 3, 2020 (the “Closing Date”), Unity Biotechnology, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan Agreement”) with Hercules Capital, Inc. (“Hercules”) pursuant to which a term loan in an aggregate principal amount of up to $80.0 million (the “Term Loan Facility”) is available to the Company in four tranches, subject to certain terms and conditions. 2.03 The information set forth in Item 1.01 of this Current Report on Form 8-K relating to the Loan Agreement is incorporated by reference into this Item 2.03. 7.01 On August 4, the Company issued a press release announcing the execution of the Loan Agreement. | d943976d8k.htm |
| 2020-07-31 | 8-K | 2020-07-31 | 2.02 Results of Operations and Financial Condition | 2.02 On July 31, 2020, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the second quarter ended June 30, 2020. | ubx-8k_20200731.htm |
| 2020-07-31 | 8-K/A | 2020-07-31 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 31, the Company entered into an Executive Employment Agreement (the “Agreement”) with Ms. Sullivan, interim Chief Financial Officer of the Company. | d31584d8ka.htm |
| 2020-07-06 | 8-K | 2020-07-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 1, Robert C. Goeltz II, the Chief Financial Officer of Unity Biotechnology, Inc., a Delaware corporation (the “Company”), notified the Company of his intention to leave his position of Chief Financial Officer of the Company to pursue another opportunity. | ubx-8k_20200701.htm |
| 2020-07-01 | 8-K | 2020-06-29 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into Material Definitive Agreement. 8.01 On July 1, 2020, Unity announced that it expects to announce 12-week results from its Phase 2 study of UBX0101, a p53/MDM2 interaction inhibitor, in patients with moderate-to-severe osteoarthritis of the knee, in the third quarter of 2020. | ubx-8k_20200629.htm |
| 2020-06-24 | 8-K | 2020-06-18 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 18, 2020, Unity Biotechnology, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). | ubx-8k_20200618.htm |
| 2020-05-07 | 8-K | 2020-05-07 | 2.02 Results of Operations and Financial Condition | 2.02 On May 7, 2020, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2020. | ubx-8k_20200507.htm |
| 2020-03-30 | 8-K | 2020-03-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 As previously reported on a Form 8-K filed with the Securities and Exchange Commission on March 2, 2020 (the “CEO Appointment 8-K”), on February 28, 2020, UNITY Biotechnology, Inc., a Delaware corporation (“UNITY” or the “Company”), appointed Anirvan Ghosh, Ph.D. as the Company’s new Chief Executive Officer (replacing Keith Leonard) and as a Class I director with a term expiring in connection with the 2022 Annual Meeting of Stockholders, in each case, effective as of March 30, 2020. 8.01 On March 30, 2020, UNITY issued a press release announcing Dr. Ghosh’s appointment and the new employment inducement grants made to Dr. Ghosh as Chief Executive Officer. | ubx-8k_20200330.htm |
| 2020-03-11 | 8-K | 2020-03-11 | 2.02 Results of Operations and Financial Condition | 2.02 On March 11, 2020, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the year ended December 31, 2019. | ubx-8k_20200311.htm |
| 2020-03-02 | 8-K | 2020-02-28 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On February 28, 2020, the Board of Directors (the “Board”) of UNITY Biotechnology, Inc., a Delaware corporation (“UNITY” or the “Company”), appointed Anirvan Ghosh, Ph.D. as the Company’s new Chief Executive Officer replacing Keith Leonard effective as of March 30, 2020. 8.01 On March 2, 2020, UNITY issued a press release announcing the appointment of Dr. Ghosh as Chief Executive Officer and a member of the Board of Directors, effective as of March 30, 2020. | d895217d8k.htm |
| 2020-02-25 | 8-K | 2020-02-25 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On February 25, 2020, Unity Biotechnology, Inc., a Delaware corporation (“UNITY” or the “Company”), issued a press release announcing, among other things, UNITY’s cash, cash equivalents and investments (unaudited) as of December 31, 2019. 8.01 On February 25, 2020, UNITY announced that the its Phase 2 study of UBX0101 in patients with moderate-to-severe osteoarthritis (“OA”) of the knee is now fully enrolled. | d893421d8k.htm |
| 2019-11-25 | 8-K | 2019-11-19 | 1.01 Entry into a Material Definitive Agreement | 1.01 On November 19, 2019, Unity Biotechnology, Inc. (“Unity” or the “Company”) entered into an amendment (the “Amendment”) to that certain license agreement, dated January 2, 2019, by and between the Company and Ascentage Pharma Group Corp. Ltd. (“Ascentage”), a clinical-stage biopharmaceutical company based in China, covering an Ascentage-controlled compound known as UBX1967 (the “Original UBX1967 License Agreement”). | d822046d8k.htm |
| 2019-11-06 | 8-K | 2019-11-06 | 2.02 Results of Operations and Financial Condition | 2.02 On November 6, 2019, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2019. | ubx-8k_20191106.htm |
| 2019-08-07 | 8-K | 2019-08-07 | 2.02 Results of Operations and Financial Condition | 2.02 On August 7, 2019, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the second quarter ended June 30, 2019. | ubx-8k_20190630.htm |
| 2019-07-30 | 8-K | 2019-07-30 | 8.01 Other Events | ubx-8k_20190730.htm | |
| 2019-07-03 | 8-K | 2019-06-18 | 8.01 Other Events | 8.01 On June 18, 2019, Unity Biotechnology, Inc., a Delaware corporation (“UNITY” or the “Company”) announced top-line results from its Phase 1 clinical study of UBX0101 in patients with moderate to severe osteoarthritis (“OA”) of the knee. | d768129d8k.htm |
| 2019-06-24 | 8-K | 2019-06-20 | 5.07 Submission of Matters to a Vote of Security Holders | ubx-8k_20190626.htm | |
| 2019-05-08 | 8-K | 2019-05-08 | 2.02 Results of Operations and Financial Condition | 2.02 On May 8, 2019, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2019. | ubx-8k_20190508.htm |
| 2019-03-06 | 8-K | 2019-03-06 | 2.02 Results of Operations and Financial Condition | 2.02 On March 6, 2019, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the year ended December 31, 2018. | ubx-8k_20190306.htm |
| 2019-01-03 | 8-K | 2019-01-03 | 1.01 Entry into a Material Definitive Agreement | 1.01 On January 2, 2019, Unity Biotechnology, Inc. (“Unity” or the “Company”) entered into a license agreement with Ascentage Pharma Group Corp. Limited (“Ascentage Pharma”), based in Hong Kong, China, covering an Ascentage-controlled compound known as UBX1967 (the “UBX1967 License Agreement”). | ubx-8k_20190103.htm |
| 2018-12-04 | 8-K | 2018-12-03 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective as of December 3, 2018, the Board of Directors (the “Board”) of Unity Biotechnology, Inc., a Delaware corporation (“Unity” or the “Company”) appointed Margo Roberts, Ph.D. as a director of the Company and as a member of the Nominating and Corporate Governance committee of the Board. | ubx-8k_20181203.htm |
| 2018-11-07 | 8-K | 2018-11-07 | 2.02 Results of Operations and Financial Condition | 2.02 On November 7, 2018, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2018. | ubx-8k_20180930.htm |
| 2018-08-09 | 8-K | 2018-08-09 | 2.02 Results of Operations and Financial Condition | 2.02 On August 9, 2018, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the second quarter ended June 30, 2018. | ubx-8k_20180809.htm |
| 2018-06-07 | 8-K | 2018-06-07 | 2.02 Results of Operations and Financial Condition | 2.02 On June 7, 2018, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2018. | d584662d8k.htm |
| 2018-05-07 | 8-K | 2018-05-07 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 5.03 On May 7, 2018, Unity Biotechnology, Inc.’s (the “Company”) amended and restated certificate of incorporation (the “Certificate of Incorporation”) filed with the Secretary of State of the State of Delaware and its amended and restated bylaws (the “Bylaws”) became effective in connection with the closing of the initial public offering of shares of the Company’s common stock. 8.01 On May 7, 2018, the Company completed its initial public offering of up to 5,000,000 shares of its common stock at a price to the public of $17.00 per share, which does not include the exercise by the underwriters of their option to purchase an additional 750,000 shares of the Company’s common stock. | d563895d8k.htm |